Sponsors

Lead Sponsor

University of Colorado, Denver

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Understanding whether the size and dynamics of the HIV reservoir are associated with adherence, measured by an objective biomarker, could have significant clinical and therapeutic implications for ART and HIV cure. 1. First, this aim will quantify levels of CA-RNA, CA-DNA, and plasma residual viremia in suppressed, HIV infected individuals and correlate them with levels of TFV-DP in DBS as a measure of cumulate drug exposure (adherence). 2. Second, this study will evaluate the changes in the HIV reservoir in relation to changes in ART adherence over time.

Related studies

RECRUITINGPhase 4

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

NCT06598397 · Human Immunodeficiency Virus (HIV), Smoking Cessation

RECRUITINGPhase 3

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800 · Human Immunodeficiency Virus (HIV) Infection

View all related studies →

Impact of ART Adherence on HIV Persistence and Inflammation

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

Improving Access to HIV Testing for Children in Uganda

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Trial snapshot

Condition

Locations shown

For caregivers